Aberdeen Group plc Buys Shares of 209,217 Vericel Corporation $VCEL

Aberdeen Group plc bought a new stake in shares of Vericel Corporation (NASDAQ:VCEL) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 209,217 shares of the biotechnology company’s stock, valued at approximately $8,902,000. Aberdeen Group plc owned approximately 0.42% of Vericel at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of VCEL. GAMMA Investing LLC raised its stake in shares of Vericel by 34.8% in the 1st quarter. GAMMA Investing LLC now owns 2,895 shares of the biotechnology company’s stock worth $129,000 after buying an additional 748 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Vericel by 29.3% in the 1st quarter. SG Americas Securities LLC now owns 12,546 shares of the biotechnology company’s stock worth $560,000 after buying an additional 2,840 shares in the last quarter. PFG Investments LLC raised its stake in shares of Vericel by 15.3% in the 1st quarter. PFG Investments LLC now owns 7,550 shares of the biotechnology company’s stock worth $337,000 after buying an additional 1,000 shares in the last quarter. Oppenheimer Asset Management Inc. raised its stake in shares of Vericel by 19.6% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 19,576 shares of the biotechnology company’s stock worth $873,000 after buying an additional 3,209 shares in the last quarter. Finally, Illinois Municipal Retirement Fund raised its stake in shares of Vericel by 6.0% in the 1st quarter. Illinois Municipal Retirement Fund now owns 27,802 shares of the biotechnology company’s stock worth $1,241,000 after buying an additional 1,573 shares in the last quarter.

Vericel Stock Down 3.0%

Shares of Vericel stock opened at $33.59 on Thursday. The stock’s fifty day moving average is $33.74 and its 200-day moving average is $38.41. The firm has a market capitalization of $1.69 billion, a PE ratio of 279.94 and a beta of 1.39. Vericel Corporation has a 12-month low of $29.24 and a 12-month high of $63.00.

Vericel (NASDAQ:VCEL) last announced its earnings results on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. Vericel had a return on equity of 2.47% and a net margin of 2.85%.The company had revenue of $63.24 million for the quarter, compared to analyst estimates of $64.61 million. During the same period in the previous year, the firm earned ($0.10) earnings per share. Vericel’s revenue for the quarter was up 20.1% compared to the same quarter last year. Analysts expect that Vericel Corporation will post 0.14 EPS for the current year.

Analyst Ratings Changes

VCEL has been the topic of a number of research reports. Canaccord Genuity Group dropped their price objective on Vericel from $61.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, August 1st. Truist Financial dropped their price objective on Vericel from $46.00 to $41.00 and set a “buy” rating on the stock in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Vericel in a research report on Wednesday, October 8th. Finally, BTIG Research lowered Vericel from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 17th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Vericel has an average rating of “Moderate Buy” and an average target price of $58.40.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.